Home › Funds › Parkman Healthcare Partners LLC › VRDN

Parkman Healthcare Partners LLC position in VRDN

VIRIDIAN THERAPEUTICS INC · Health Care

Parkman Healthcare Partners LLC reported holding 1,674,834 shares of VRDN (VIRIDIAN THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$34.5M, representing 3.11% of its reported portfolio and ranking #7 among its reported holdings. Parkman Healthcare Partners LLC has disclosed VRDN holdings in 9 of the last 9 reported quarters, going back to Q3 2024.

Latest position (Q3 2026)1.67M sh
Reported value held$34.48M
Portfolio Weight3.11%
First reportedQ3 2024
Last changeAdd
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How Parkman Healthcare Partners LLC's VRDN position evolved

Parkman Healthcare Partners LLC first disclosed a stake in VRDN in Q3 2024 at 425,000 shares (US$9.7M). The position peaked in Q3 2026 at 1,674,834 shares, worth US$34.5M. Across 9 filings, Parkman Healthcare Partners LLC increased the stake 4 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,674,834 shares valued at US$34.5M — an increase of 297,258 shares quarter over quarter.. Notable position changes include a 156% increase in Q4 2024 (shares fell 30% over the following quarter), a 32% trim in Q4 2025 (shares fell 37% over the following quarter), a 147% increase in Q2 2026 (shares rose 12% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2024 425.00K $9.67M New
Q4 2024 1.09M $20.85M Add
Q1 2025 1.06M $14.35M Reduce
Q2 2025 1.30M $18.16M Add
Q3 2025 1.15M $24.91M Reduce
Q4 2025 788.08K $24.52M Reduce
Q1 2026 557.94K $10.91M Reduce
Q2 2026 1.38M $25.31M Add
Q3 2026 1.67M $34.48M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRDN and 13F data

VRDN (VIRIDIAN THERAPEUTICS INC) is a Health Care company. 42 other funds we track also report a position in VRDN — the largest reported positions include Paradigm Biocapital Advisors LP (US$227.1M), Kynam Capital Management, LP (US$126.6M), Bellevue Group AG (US$123.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRDN

All VRDN fund holders →

FAQ

How long has Parkman Healthcare Partners LLC held VRDN?

Parkman Healthcare Partners LLC has disclosed VRDN holdings in 9 of the last 9 reported quarters, going back to Q3 2024.

What is Parkman Healthcare Partners LLC's current position in VRDN?

As of Q3 2026, Parkman Healthcare Partners LLC holds 1.67M shares of VRDN (VIRIDIAN THERAPEUTICS INC), valued at $34.48M, representing 3.11% of its reported portfolio and ranking #7.

Has Parkman Healthcare Partners LLC been buying or selling VRDN?

In the latest 13F filing (Q3 2026), Parkman Healthcare Partners LLC increased its position in VRDN. The position peaked in Q3 2026 at 1.67M shares.

Which other funds hold VRDN?

Other major institutional holders of VRDN include Paradigm Biocapital Advisors LP, Kynam Capital Management, LP, Bellevue Group AG, among 42 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.